According to TipRanks.com, Leone is a 5-star analyst with an average return of 20.5% and a 66.5% success rate. Leone covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, Allogene Therapeutics, and Ayala Pharmaceuticals.
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $657.86, implying a 33.1% upside from current levels. In a report issued on February 5, J.P. Morgan also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Regeneron’s market cap is currently $52.03B and has a P/E ratio of 15.90. The company has a Price to Book ratio of 4.72.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.
Read More on REGN: